Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.

Karschner EL, Swortwood MJ, Hirvonen J, Goodwin RS, Bosker WM, Ramaekers JG, Huestis MA.

Drug Test Anal. 2016 Jul;8(7):682-9. doi: 10.1002/dta.1825. Epub 2015 Jun 11.

2.

Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment.

Lee D, Schroeder JR, Karschner EL, Goodwin RS, Hirvonen J, Gorelick DA, Huestis MA.

Am J Addict. 2014 May-Jun;23(3):234-42. doi: 10.1111/j.1521-0391.2014.12088.x.

3.

In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis.

Scheidweiler KB, Schwope DM, Karschner EL, Desrosiers NA, Gorelick DA, Huestis MA.

Clin Chem. 2013 Jul;59(7):1108-17. doi: 10.1373/clinchem.2012.201467. Epub 2013 Mar 21.

4.

Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws.

Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, Huestis MA.

Clin Chem. 2013 Mar;59(3):519-26. doi: 10.1373/clinchem.2012.195503.

5.

Psychomotor function in chronic daily Cannabis smokers during sustained abstinence.

Bosker WM, Karschner EL, Lee D, Goodwin RS, Hirvonen J, Innis RB, Theunissen EL, Kuypers KP, Huestis MA, Ramaekers JG.

PLoS One. 2013;8(1):e53127. doi: 10.1371/journal.pone.0053127. Epub 2013 Jan 2.

6.

Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?

Lee D, Karschner EL, Milman G, Barnes AJ, Goodwin RS, Huestis MA.

Drug Alcohol Depend. 2013 Jun 1;130(1-3):68-76. doi: 10.1016/j.drugalcdep.2012.10.011. Epub 2012 Nov 10.

7.

Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC.

Karschner EL, Schwope DM, Schwilke EW, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA.

Drug Alcohol Depend. 2012 Oct 1;125(3):313-9. doi: 10.1016/j.drugalcdep.2012.03.005. Epub 2012 Mar 29.

8.

Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.

Schwope DM, Karschner EL, Gorelick DA, Huestis MA.

Clin Chem. 2011 Oct;57(10):1406-14. doi: 10.1373/clinchem.2011.171777. Epub 2011 Aug 11.

9.

Subjective and physiological effects after controlled Sativex and oral THC administration.

Karschner EL, Darwin WD, McMahon RP, Liu F, Wright S, Goodwin RS, Huestis MA.

Clin Pharmacol Ther. 2011 Mar;89(3):400-7. doi: 10.1038/clpt.2010.318. Epub 2011 Feb 2.

10.

Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.

Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA.

Clin Chem. 2011 Jan;57(1):66-75. doi: 10.1373/clinchem.2010.152439. Epub 2010 Nov 15.

11.

Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasma.

Karschner EL, Barnes AJ, Lowe RH, Scheidweiler KB, Huestis MA.

Anal Bioanal Chem. 2010 May;397(2):603-11. doi: 10.1007/s00216-010-3599-6. Epub 2010 Mar 20.

12.

Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.

Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Herning RI, Cadet JL, Huestis MA.

J Anal Toxicol. 2009 Oct;33(8):469-77.

13.

Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.

Schwilke EW, Schwope DM, Karschner EL, Lowe RH, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA.

Clin Chem. 2009 Dec;55(12):2180-9. doi: 10.1373/clinchem.2008.122119. Epub 2009 Oct 15.

14.

Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?

Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Pope HG, Herning R, Cadet JL, Huestis MA.

Addiction. 2009 Dec;104(12):2041-8. doi: 10.1111/j.1360-0443.2009.02705.x. Epub 2009 Oct 5.

15.

Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing.

Schwilke EW, Karschner EL, Lowe RH, Gordon AM, Cadet JL, Herning RI, Huestis MA.

Clin Chem. 2009 Jun;55(6):1188-95. doi: 10.1373/clinchem.2008.114405. Epub 2009 Mar 5.

17.

An enzyme-coupled continuous spectrophotometric assay for S-adenosylmethionine-dependent methyltransferases.

Dorgan KM, Wooderchak WL, Wynn DP, Karschner EL, Alfaro JF, Cui Y, Zhou ZS, Hevel JM.

Anal Biochem. 2006 Mar 15;350(2):249-55. Epub 2006 Feb 7.

PMID:
16460659
18.

Synthesis of LuxS inhibitors targeting bacterial cell-cell communication.

Alfaro JF, Zhang T, Wynn DP, Karschner EL, Zhou ZS.

Org Lett. 2004 Sep 2;6(18):3043-6.

PMID:
15330583

Supplemental Content

Loading ...
Support Center